Product
Racotumomab
1 clinical trial
1 indication
Indication
NeuroblastomaClinical trial
Open-label, Multicenter, Phase II Immunotherapy Study With Racotumomab in Patients With High-risk NeuroblastomaStatus: Completed, Estimated PCD: 2022-11-01
1 clinical trial
1 indication